Ionis Pharmaceuticals (IONS) Leases (2010 - 2026)

Ionis Pharmaceuticals has reported Leases for 8 years, with the latest figure at $235.1 million in Q1 2026.

• For the quarter ending Q1 2026, Leases rose 47.59% year-over-year to $235.1 million; the trailing twelve-month figure through Mar 2026 stood at $235.1 million (up 47.59% YoY), and the FY2025 full-year result was $238.5 million, up 47.38% from the prior year.
• Leases for Q1 2026 stood at $235.1 million, down from $238.5 million in the prior quarter.
• The five-year high for Leases was $242.0 million in Q3 2025, with the low at $159.3 million in Q1 2025.
• Average Leases over 5 years is $184.6 million, with a median of $173.1 million recorded in 2023.
• Year-over-year, Leases surged 910.04% in 2022 and decreased 6.0% in 2025.
• Tracing IONS's Leases over 5 years: stood at $181.5 million in 2022, then retreated by 5.31% to $171.9 million in 2023, then slipped by 5.84% to $161.9 million in 2024, then jumped by 47.38% to $238.5 million in 2025, then dropped by 1.46% to $235.1 million in 2026.
• The last three Leases figures came in at $235.1 million (Q1 2026), $238.5 million (Q4 2025), and $242.0 million (Q3 2025), per Business Quant data.

Peer Comparison